CURRENT VIEW OF HORTON'S DISEASE: ANALYSIS OF ITS CASES IN THE KHABAROVSK TERRITORY
https://doi.org/10.14412/1995-4484-2011-1459
Abstract
Objective: to analyze the incidence of giant-cell arteritis (GCA) in the Khabarovsk Territory.
Subjects and methods. Ten (11.6%) cases of GCA identified during a 20-year prospective follow-up and treatment of 89 patients with polymyalgia rheumatica (PR) and GCA were analyzed. The rate of some criteria for the diagnosis of GCA was estimated; its onset and paraclinical data were described. The study enrolled women aged 67.3±2.1 years (range 59 to 76 years).
Results and discussion. GCA concurrent with PR was observed in 70% of cases. In addition to temporal arteritis, there was a clinical picture of involvements of the parietal (50%), ocular (30%), occipital (30%), and coronary (10%) arteries. Scalp involvement with necrosis in the parietal area was found in one case. The diagnosis was established after an average of 71±1.6 months. All had elevated ESR, up to 110.2±3.1 on average after Westergren. Seven patients were treated with prednisolone 1.0 mg/kg body weight; due to contraindications,
6 patients had 0.5 mg/kg in combination with pulse therapy with cyclophosphanum 1000 mg intravenously, dropwise once monthly. One female patient died from stroke 4 months later. The late period was marked by the development of osteoporosis with fractures in 2 cases, diabetes mellitus and hypertension in 2, and cancer of the cervix uteri (successfully cured) in one case. Vision loss was seen in one patient whose diagnosis was made 1.5 years later.
References
1. <div><p>Бунчук Н.В. Ревматические заболевания пожилых. М.: МЕДпрессинформ, 2010; с. 6-136</p><p>Насонов Е.Л., Баранов А.А., Шиллкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999; 614 с</p><p>Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;714 с.</p><p>Horton B.T., Magath T.B., Brown G.E. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932;7:700-1.</p><p>Weyand C.M., Goronzy J.J. Arterial wall injury in giant cell arteritis. Arthr Rheum 1999;42:844-53.</p><p>Weyand C.M., Goronzy J.J. Mediumand large-vessel vasculitis. N Engl J Med 2003;349:160-9.</p><p>Evans J.M., Hunder G.G. Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2000;26:493-515.</p><p>Uddhammar A., Eriksson A.L., Nystrom L. et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42.</p><p>Franzеn P., Sutinen S., von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 1992;19:273-6.</p><p>Hunder G.G. Epidemiology of giant cell arterits. Cleve Clin J Med 2002;69(Suppl. 2):S1179-S1182</p><p>Lawrence R.C., Helmick C.G., Arnett F.C. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 1998;41:778-99.</p><p>Machado E.B., Michet C.J., Ballard D.J. et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthr Rheum 1988;31:745-9.</p><p>Gay M.A., Alonso M.D., Aguero J.J. et al. Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. J Rheumatol 1992;19:277-80.</p><p>Smeeth L., Cook C., Hall A.J. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990 to 2001. Ann Rheum Dis 2006;65:1093-8.</p><p>Dababneh A., Gonzalez-Gay M.A., Garcia-Porrua C. et al. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5.</p><p>Wagner A.D., Bjornsson J., Bartley G.B. et al. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996;148:1925-33.</p><p>Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-61.</p><p>Weyand C.M., Hunder N.N., Hicok K.C. et al. Comparison of polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis by genetic linkage analysis. Arthr Rheum 1994;37:514-20</p><p>Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91</p><p>Weyand C.M., Tetzlaff N., Bjornsson J. et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthr Rheum 1997;40:19-26.</p><p>Weyand C.M., Goronzy J.J. Giant-Cell Arteritis and Polymyalgia Rheumatica. Ann Inter Med 2003;139:505-15</p><p>Hunder G.G., Valente R.M. Giant cell arteritis: Clinical aspects. In: Hoffman G.S., Weyand C.M., eds. Inflammatory Diseases of Blood Vessels. New York: Marcel Dekker, 2002;425-41.</p><p>Hunder G.G., Bloch D.A., Michel B.A. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthr Rheum 1990;33:1122-8.</p><p>Leeb B.F., Bird H.A. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63(10):1279-83.</p><p>Leeb B.F., Bird H.A., Nesher G. et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European collaborating Polymyalgia Rheumatica group (subcommittee of ESCISIT). Ann Rheum Dis 2003;62:1189-94.</p><p>Leeb B.F., Rintelen B., Sautner J. The Polymyalgia Rheumatica Activity Score in Daily Use: Proposal for a Definition of Remission. Arthr Rheum (Arthr Care Res) 2007;57(5):810-5.</p><p>Leeb B.F. Disease activity assessment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) [abstract]. Rheumatology (Oxford) 2005;44 (Suppl. 3): 5-6.</p><p>Achkar A.A., Hunder G.G., Gabriel S.E. Effect of previous corticosteroid treatment on temporal artery biopsy results [Letter]. Ann Intern Med 1998;128:410</p><p>Brack A., Martinez-Taboada V., Stanson A. et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthr Rheum 1999;42:311-7.</p><p>Ghanchi F.D., Dutton G.N. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 1997;42:99-123.</p><p>Nesher G., Nesher R., Rozenman Y., Sonnenblick M. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol 2001;28:2046-8.</p><p>Liu G.T., Glaser J.S., Schatz N.J., Smith J.L. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-85.</p><p>Levine S.M., Hellmann D.B. Giant cell arteritis. Curr Opin Rheumatol 2002;14:3-10</p><p>Tovilla-Canales J.L. Ocular manifestations of giant cell arteritis. Curr Opin Ophthalmol 1998;9:73-9.</p><p>Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502-7</p><p>Evans J.M., Bowles C.A., Bjornsson J. et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthr Rheum 1994;37: 1539-47</p><p>Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis [review]. N Engl J Med 2002;347:261-71.</p><p>Weyand C.M., Goronzy J.J. Arterial wall injury in giant cell arteritis. Arthr Rheum 1999;42:844-53.</p><p>Cantini F., Salvarani C., Olivieri I. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case control study. J Rheumatol 2001;28:1049-55.</p><p>Nordborg E., Nordborg C., Bengtsson B.A. Giant cell arteritis. Curr Opin Rheumatol 1992;4:23-30</p><p>Cantini F., Salvarani C., Olivieri I. et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthr Rheum 2000;30:17-24.</p><p>Jones J.G., Hazleman B.L. ESR in polymyalgia rheumatica and giant cell arteritis [Letter]. Ann Rheum Dis 1983;42:702-3.</p><p>Martinez-Taboada V.M. Giant cell arteritis with an erythrocyte sediemtation rate lower than 50. Clin Rheumatol 2000;19:73-5.</p><p>Salvarani C., Hunder G.G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a populationbased study. Arthr Rheum 2001;45:140-5.</p><p>Seo Ph., Stone J. Large-Vessel Vasculitis. Arthr Rheum 2004;15:128-39.</p><p>Gonzales-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5.</p><p>Genereau T., Lortholary O., Pottier M.A. et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthr Rheum 1999;42:2674-81.</p><p>Foroozan R., Danesh-Meyer H., Savino P.J. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 2002;109:1267-71</p><p>Lie J.T. Temporal artery biopsy diagnosis of giant cell arteritis: lessons from 1109 biopsies. Anat Pathol 1996;1:69-97.</p><p>Duhaut P., Pinede L., Bornet H. et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Ann Rheum Dis 1999;58:335-41</p><p>Allison M., Gallagher P. Temporal artery biopsy and corticosteroid treatment. Ann Rhem Dis 1984;43:416-7</p><p>Schmidt W.A., Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology 2002;4:46-52.</p><p>Schmidt W.A. Doppler ultrasonography in the diagnosis of giant cell arteritis. Clin Exp Rheumatol 2000;18(Suppl. 20):40-2.</p><p>Birkhead N.C., Wagener H.P., Schick R.M. Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which lesion was proven at biopsy. JAMA 1957;163:821-7</p><p>Myklebust G., Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective twoyear study in 273 patients. Scand J Rheumatol 2001;30:260-7.</p><p>Jover J.A., Hernandez-Garcia C., Morado I.C. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.</p><p>Krall P.L., Mazanec D.J., Wilke W.S. Methotrexate for corticosteroidresistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1989;56:253-7.</p><p>Spiera R.F., Mitnick H.J., Kupersmith M. et al. A prospective, doubleblind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001;19:495-501.</p><p>Weyand C.M., Kaiser M., Yang H. et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthr Rheum 2002;46:457-66.</p><p>Weyand C.M., Fulbright J.W., Hunder G.G. et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthr Rheum 2000;43:1041-8.</p><p>Hagihara K., Kawase I., Tanaka T., Kishimoto Т. Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica. J Rhematol 2010;37(5):1075-6.</p></div><br />
Review
For citations:
Otteva E.N., Kocherova T.Yu. CURRENT VIEW OF HORTON'S DISEASE: ANALYSIS OF ITS CASES IN THE KHABAROVSK TERRITORY. Rheumatology Science and Practice. 2011;49(5):38-45. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1459
Views:
1842
Email this article 